source
- Biomarker testing guides endometrial cancer treatment and highlights gaps in second-line options after immunotherapyThe discussion highlighted that performing biomarker testing at diagnosis is now standard for endometrial cancer, helping decide between targeted therapies and immunotherapy. The experts described…
- Safety-boosting drug may weaken gene therapy efficacy in Dravet syndrome trialEncoded Therapeutics studied a drug meant to improve the safety of gene therapy in children with Dravet syndrome, a severe genetic epilepsy. In the trial of 21 participants, most received steroids…